熱門資訊> 正文

默克公司将开始艾滋病毒预防药物的后期试验

2025-07-15 00:12

Merck (NYSE:MRK) said on Monday that it will start late-stage clinical trials for its oral drug, MK-8527, aimed at preventing HIV.
In partnership with the Gates Foundation, the MK-8527-010 trial will focus on evaluating MK-8527 for women and adolescent girls in sub-Saharan Africa.
The trial is expected to start enrolling participants in August 2025, the company said.

More on Merck

Merck Buys Verona Pharma: A Good Deal, But M&A Spree Must Continue
Merck & Co.: A Pharma Titan At A Discount
Dividend Yield Theory Says Merck Is A Buy
Key deals this week: Meta, Boyd Gaming, Merck, Sandstorm Gold, Capgemini and more
FDA mulls faster drug reviews in exchange for lower prices in U.S.- Bloomberg

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。